Jeyakumar, N., Torres, N., Godbole, S., Yamamoto, F., Zhang, B., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, L., Lowsky, R., Negrin, R., Rezvani, A., Shizuru, J., Sidana, S., Smith, M., Weng, W., Miklos, D., Schwede, M., Mannis, G., Zhang, T., Muffly, L., Kennedy, V. (2025). Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT. Blood. https://doi.org/10.1182/blood-2025-2525